Literature DB >> 10396021

Up-regulation of clusterin (sulfated glycoprotein-2) in pancreatic islet cells upon streptozotocin injection to rats.

I S Park1, Y Z Che, M Bendayan, S W Kang, B H Min.   

Abstract

Clusterin is a heterodimeric glycoprotein which has been shown to play important roles in programmed cell death and/or in tissue reorganization not only during embryonic development but also in damaged tissues. Recently, we reported the transient induction of clusterin in pancreatic endocrine cells during early developmental stages of islet formation. In the present study, we have investigated the expression of clusterin in pancreatic tissue of streptozotocin-treated rats which were undergoing extensive islet tissue reorganization due to degeneration of insulin beta cells. Clusterin was found in endocrine cells identified as glucagon-secreting alpha cells at the periphery of the islet. Using immunoelectron microscopy, clusterin-positive cells showed the typical ultrastructural features of pancreatic alpha cells. In addition, colocalization of clusterin and glucagon in the same secretory granules was shown by double immunogold labeling. These results imply that clusterin is a secretory molecule having endocrine and/or paracrine actions in parallel with glucagon. Further, we noted that clusterin expression was increased in pancreatic alpha cells during the process of beta cell death upon streptozotocin injection. The increase was significant as early as 1-3 h after streptozotocin treatment prior to any morphological alteration of islet beta cell and any manifestation of hyperglycemia. The expression of clusterin was steady-stately up-regulated during the process of islet reorganization caused by streptozotocin-induced cytotoxic injury. Therefore, we suggest that clusterin might be considered as a molecule induced by both embryonic development and drug-induced reorganization of the endocrine pancreas. Since clusterin expression is up-regulated in alpha cells, but not in beta cells undergoing degeneration, it may play a protective role against the cytotoxic insult.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396021     DOI: 10.1677/joe.0.1620057

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  Neural stem cell heterogeneity demonstrated by molecular phenotyping of clonal neurospheres.

Authors:  Oleg N Suslov; Valery G Kukekov; Tatyana N Ignatova; Dennis A Steindler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

2.  Clusterin induces differentiation of pancreatic duct cells into insulin-secreting cells.

Authors:  B M Kim; S Y Kim; S Lee; Y J Shin; B H Min; M Bendayan; I S Park
Journal:  Diabetologia       Date:  2006-01-13       Impact factor: 10.122

3.  Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival.

Authors:  Z Liu; V Stanojevic; S Avadhani; T Yano; J F Habener
Journal:  Diabetologia       Date:  2011-05-13       Impact factor: 10.122

4.  Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.

Authors:  Thomas W Czeczok; Kristen M Stashek; Jessica E Maxwell; Thomas M O'Dorisio; James R Howe; Jason L Hornick; Andrew M Bellizzi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-02

5.  An expression profile of human pancreatic islet mRNAs by Serial Analysis of Gene Expression (SAGE).

Authors:  C Cras-Méneur; H Inoue; Y Zhou; M Ohsugi; E Bernal-Mizrachi; D Pape; S W Clifton; M A Permutt
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

6.  Exon-skipping strategy by ratio modulation between cytoprotective versus pro-apoptotic clusterin forms increased sensitivity of LNCaP to cell death.

Authors:  Abdellatif Essabbani; Luis Garcia; Maria Josè Zonetti; Tommaso Fisco; Sabina Pucci; Gilles Chiocchia
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.